Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

More than 15 years ago, the first generation of genetically engineered mouse (GEM) models of prostate cancer was introduced. These transgenic models utilized prostate-specific promoters to express SV40 oncogenes specifically in prostate epithelium. Since the description of these initial models, there have been a plethora of GEM models of prostate cancer representing various perturbations of oncogenes or tumor suppressors, either alone or in combination. This review describes these GEM models, focusing on their relevance for human prostate cancer and highlighting their strengths and limitations, as well as opportunities for the future.

Original publication

DOI

10.1007/s10555-012-9409-1

Type

Journal article

Journal

Cancer Metastasis Rev

Publication Date

06/2013

Volume

32

Pages

109 - 122

Keywords

Animals, Disease Models, Animal, Genes, Tumor Suppressor, Humans, Male, Mice, Mice, Transgenic, Neoplasm Metastasis, PTEN Phosphohydrolase, Precancerous Conditions, Prostatic Neoplasms, Proto-Oncogenes, Signal Transduction